Esperion files new drug submissions in Canada for Nexletol and Nexlizet as a treatment for reducing bad cholesterol and ...

Esperion (ESPR) has filed New Drug Submissions to Health Canada for NEXLETOL and NEXLIZET, once-daily, accessible, oral non-statin medications ...

A UCLA study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as ...

Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...

If you have high cholesterol, your doctor may prescribe you with a type of statin. Here’s what you need to know. Statins are a group of medications used to treat high cholesterol. They work by ...

a class of drug that effectively reduces cholesterol. Guidelines for doctors do not recommend prescribing statins to diabetic patients unless they have high cholesterol levels. But the new ...

Overall, a 20% decrease in LDL cholesterol was seen. Participants reported that they would have found more information on drug interactions ... make statins unavailable to non-insured or indigent ...

A new study has outlined a new framework that researchers say would improve predictive power of genetics to determine how well a patient would respond to commonly prescribed medications as well as the ...

A UCLA study has outlined a new framework that researchers say would improve the predictive power of genetics to determine ...

has submitted New Drug Submissions to Health Canada for two cholesterol-lowering medications, NEXLETOL and NEXLIZET, the company announced today. These oral, non-statin drugs are designed to ...

ANN ARBOR, Mich. - Esperion (NASDAQ: NASDAQ:ESPR), which has seen remarkable revenue growth of 187% over the last twelve months, has submitted New Drug Submissions to Health Canada for two cholesterol ...